Neurol. praxi. 2012;13(4):211-214

Assessing quality of life of patients with multiple sclerosis

MUDr.Ema Kantorová, Ph.D., prof.MUDr.Egon Kurča, Ph.D., MUDr.Jozef Michalik
Neurologická klinika Jesseniovej LF UK a Univerzitnej nemocnice, Martin

Multiple sclerosis is a chronic inflammatory and degenerative disease of the central nervous system, usually affecting young adult

individuals in the productive age. Multiple sclerosis is among the diseases that significantly reduce the quality of life of patients, thus

principally affecting the lives of whole families. Therefore, from a medical point of view, assessment of quality of life of patients is an

important part of the therapeutic management of patients and often even determines a change in the treatment strategy. Pharmacoeconomic

issues are another important aspect of the treatment of patients with multiple sclerosis.

Keywords: multiple sclerosis, quality of life assessment, treatment strategy, rate of costs incurred

Published: July 31, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kantorová E, Kurča E, Michalik J. Assessing quality of life of patients with multiple sclerosis. Neurol. praxi. 2012;13(4):211-214.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Blahova-Dusankova J, Kalincik T, Dolezal T, Kobelt G, Havrdova E. Cost of multiple sclerosis in the Czech Republic: The COMS Study. Mult Scler 2011; Sep 30. Epub ahead of print. Go to original source... Go to PubMed...
    2. Cohen JA, Barkhof F, Comi G and collaborators. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Eng J Med 2010; 362: 387-401. Go to original source... Go to PubMed...
    3. Cohen JA, Barkhof F, Comi G and collaborators. Oral fingolimod (FTY720) improves performance of daily activities compared with intramuscular interferon beta-1a: Patient-reported indices for multiple sclerosis (PRIMUS activities). results from the TRANSFORMS phase 3 trial. International J MS Care 2010; 12(Suppl 1): 16.
    4. Edgley K, Sullivan M, Dehoux E. A survey of multiple sclerosis: II. Determinants of employment status. Canadian Journal of Rehabilitation 1991; 3: 127-132.
    5. Fisher JS, Rudick RA, Cutter GR, Reingold SC. The multiple sclerosis functional composite measure (MSFC): an integrated approach to MS clinical assesment. Mult Scler 1999; 4: 244-250. Go to original source... Go to PubMed...
    6. Heesen C, Bohm J, Reich C, Goebel M, Gold SM. Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable. Mult Scler 2008; 14: 988-991. Go to original source... Go to PubMed...
    7. Kappos L, Radue EW, O´Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P. A placebo-controlled trial of oral fingolimod (FTY720) or placebo 24-month results from FREEDOMS. ECTRIMS 2010, Abstrakt 434, Immunomodulation 1, October 14.
    8. Kobelt G, Textier-Richard B, Lingren P. The long term cost of multiple sclerosis in France and potential changes with disease-modifying interventions. Mult Scler 2009; 15: 741-751. Go to original source... Go to PubMed...
    9. Olofsson S, Wickstrom A, Häger G, Persson U, Svenningsson A. Effect of treatment with natalizumab on ability to work in people with multiple sclerosis: productivity gain based on direct measurement of work capacity before and after 1 year of treatment. BioDrugs 2011; 25(5): 299-306. Go to original source... Go to PubMed...
    10. Phillips JT, Giovannoni G, Lublin FD, O'Connor PW, Polman CH, Willoughby E, Aschenbach W, Pace A, Hyde R, Munschauer FE. Sustained improvement in expanded disability status scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effect with natalizumab in patients with relapsing multiple sclerosis. Mult Scler Journal 2011; 17(8): 970-979. Go to original source... Go to PubMed...
    11. Rice GP, Oger J, Duguette P, Francis GS, Bélanger M, Laplante S, Grenier JF. Treatment with interferon beta 1-b improves quality of life in multiple sclerosis. Can J Neurol Sci 1999; 26(4): 276-282. Go to original source... Go to PubMed...
    12. Salter AR, Cutter GR, Tyry T, Marrie RA, Vollmer T. Impact of loss of mobility on instrumental activities of daily living and socioeconomic status in patients with MS. Curr Med Res Opin 2010; 26(2): 493-500. Go to original source... Go to PubMed...
    13. Sánchez-de la Rosa R, Sabater E, Casado MA, Arroyo R. Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients. Journal of Medical Economics 2012; 15(3): 1-10. Go to original source... Go to PubMed...
    14. Simone IL, Ceccarelli A, Tortella C, Bellacosa A, Pellegrini F, Plasmati I, DeCaro MF, Lopez M, Girolamo F, Livrea P. Influence of interferon beta treatment on quality of life in multiple sclerosis patients. Health Qual Life Outcomes 2006; 12(4): 96. Go to original source... Go to PubMed...
    15. Štourač P, Praksová P, Kontrová I, Hladíková M, Okáčová I, Benešová Y. Glatiramer acetát (Copaxone(R)) v léčbě atakovité roztroušené sklerózy mozkomíšní - klinická účinnost a bezpečnostní profil. Cesk Slov Neurol N 2011; 74/107(4): 447-454.
    16. Švehlíková L, Heretik A, ml. Kvalita života - o čom to hovoríme? Psychiatria - psychoterapia - psychosomatika 2008; 15(3): 194-198.
    17. Tesař T, Babela R, Foltán V, Ilavská A. Farmakoekonomika a hodnotenie kvality života pacientov. Via pract 2008; 5(7/8): 332.

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.